AIMS/HYPOTHESIS: Recent studies have shown that the inflammatory process is involved in the pathogenesis of diabetic nephropathy. Fourteen-membered ring macrolides, including erythromycin, have anti-inflammatory, as well as antibacterial effects. The aim of this study was to investigate the renoprotective effects of erythromycin in streptozotocin (STZ)-induced diabetic rats. METHODS: STZ-induced diabetic rats were treated orally with erythromycin (5 mg/kg body weight) or vehicle every day for 8 weeks. To evaluate the effect of erythromycin treatment, we measured urinary albumin excretion, and examined the following in the kidney: histological changes, the expression of intercellular adhesion molecule-1 (ICAM-1), macrophage infiltration, and nuclear factor-kappa B (NF-kappaB) activity. RESULTS: Erythromycin significantly reduced urinary albumin excretion without affecting blood glucose levels and blood pressure. Erythromycin also attenuated glomerular hypertrophy, mesangial expansion, macrophage infiltration and ICAM-1 expression in renal tissues. The expression of the gene encoding TGFB1 (also known as TGF-beta1), type IV collagen protein production and NF-kappaB activity in renal tissues were increased in diabetic rats and reduced by erythromycin treatment. CONCLUSIONS/ INTERPRETATION: Erythromycin prevented renal injuries without changes of blood glucose levels and blood pressure in experimental diabetic rats. These results suggest that the renoprotective effects of erythromycin are based on its anti-inflammatory effect via suppression of NF-kappaB activation. Modulation of microinflammation with erythromycin may provide a new approach for diabetic nephropathy.
AIMS/HYPOTHESIS: Recent studies have shown that the inflammatory process is involved in the pathogenesis of diabetic nephropathy. Fourteen-membered ring macrolides, including erythromycin, have anti-inflammatory, as well as antibacterial effects. The aim of this study was to investigate the renoprotective effects of erythromycin in streptozotocin (STZ)-induced diabeticrats. METHODS:STZ-induced diabeticrats were treated orally with erythromycin (5 mg/kg body weight) or vehicle every day for 8 weeks. To evaluate the effect of erythromycin treatment, we measured urinary albumin excretion, and examined the following in the kidney: histological changes, the expression of intercellular adhesion molecule-1 (ICAM-1), macrophage infiltration, and nuclear factor-kappa B (NF-kappaB) activity. RESULTS:Erythromycin significantly reduced urinary albumin excretion without affecting blood glucose levels and blood pressure. Erythromycin also attenuated glomerular hypertrophy, mesangial expansion, macrophage infiltration and ICAM-1 expression in renal tissues. The expression of the gene encoding TGFB1 (also known as TGF-beta1), type IV collagen protein production and NF-kappaB activity in renal tissues were increased in diabeticrats and reduced by erythromycin treatment. CONCLUSIONS/ INTERPRETATION:Erythromycin prevented renal injuries without changes of blood glucose levels and blood pressure in experimental diabeticrats. These results suggest that the renoprotective effects of erythromycin are based on its anti-inflammatory effect via suppression of NF-kappaB activation. Modulation of microinflammation with erythromycin may provide a new approach for diabetic nephropathy.
Authors: N Miyatake; K Shikata; H Sugimoto; M Kushiro; Y Shikata; S Ogawa; Y Hayashi; M Miyasaka; H Makino Journal: Nephron Date: 1998 Impact factor: 2.847
Authors: C Sassy-Prigent; D Heudes; C Mandet; M F Bélair; O Michel; B Perdereau; J Bariéty; P Bruneval Journal: Diabetes Date: 2000-03 Impact factor: 9.461
Authors: Rodrigo M C Pestana; Caroline P Domingueti; Rita C F Duarte; Rodrigo B Fóscolo; Janice S Reis; Ana Maria S Rodrigues; Laís B Martins; Lirlândia P Sousa; Daniela P Lage; Cláudia N Ferreira; Adaliene V M Ferreira; Ana P Fernandes; Karina B Gomes Journal: Immunol Res Date: 2016-08 Impact factor: 2.829
Authors: P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis Journal: Eur J Clin Pharmacol Date: 2011-11-22 Impact factor: 2.953
Authors: R Kodera; K Shikata; H U Kataoka; T Takatsuka; S Miyamoto; M Sasaki; N Kajitani; S Nishishita; K Sarai; D Hirota; C Sato; D Ogawa; H Makino Journal: Diabetologia Date: 2011-01-21 Impact factor: 10.122
Authors: Jennifer M Sasser; Jennifer C Sullivan; Janet L Hobbs; Tatsuo Yamamoto; David M Pollock; Pamela K Carmines; Jennifer S Pollock Journal: J Am Soc Nephrol Date: 2006-12-13 Impact factor: 10.121